Repligen Corporation Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 27, 2026 results vs estimates
Repligen Corporation Forecast
Repligen Corporation short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 54.7% a year, a typical one-standard-deviation range is 174.10–203.18 over a week, 158.84–218.44 over a month and 85.41–291.87 over a year. (Signals as of 1 Nov 2026.)
Repligen Corporation Price Chart
Repligen Corporation Factors
YoY +2.1%
YoY +15.7%
YoY +22.3%
YoY +1.1%
YoY −14.1%
YoY −684.5%
YoY +16.2%
YoY +185.1%
YoY +203.0%
YoY +18.2%
YoY +18.1%
YoY +64.7%
YoY +0.1%
YoY −14.3%
YoY +16.3%
Repligen Corporation fundamentals: income statement, balance sheet & cash flow
Repligen Corporation reported revenue of $738.3m and net income of $48.9m in FY2025, the year ended 31 December 2025 — revenue up 16.4% and net income up 291.6% on the prior year. Free cash flow was $93.9m. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 738.3 | 634.4 | 632.4 | 801.5 | 670.5 |
| Cost of revenue | 390.6 | 359.8 | 353.9 | 345.8 | 279.3 |
| Gross profit | 347.6 | 274.6 | 278.4 | 455.7 | 391.3 |
| Research & development | 54.2 | 43.2 | 42.7 | 43.9 | 34.3 |
| Operating income | 59.6 | -35.1 | 47.7 | 224.7 | 167.2 |
| EBITDA | 182.5 | 80.3 | 145.3 | 277.3 | 203.3 |
| Interest expense | 23.2 | 22.6 | 10.0 | 3.0 | 12.7 |
| Pre-tax income | 62.4 | -27.0 | 56.7 | 219.1 | 153.5 |
| Income tax | 13.5 | -1.5 | 21.1 | 33.2 | 25.3 |
| Net income | 48.9 | -25.5 | 35.6 | 186.0 | 128.3 |
Download Repligen Corporation fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.RGEN.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Repligen Corporation
Explore MacroFinance macro & markets research and analysis.
Repligen Corporation Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Repligen Corporation; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Repligen Corporation’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Repligen Corporation (United States)
Repligen Corporation is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Repligen Corporation?
What is the latest Repligen Corporation price?
Is Repligen Corporation in an uptrend?
How volatile is Repligen Corporation?
What factors affect Repligen Corporation?
Which trading strategies trade Repligen Corporation?
How are Repligen Corporation returns analysed?
Where can I download free Repligen Corporation historical data?
Free Repligen Corporation historical data (last 10 years)
Browse or instantly download the last 10 years of Repligen Corporation daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.RGEN.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 163.81 |
| 2026-11-19 | 170.29 |
| 2026-11-18 | 172.67 |
| 2026-11-17 | 162.18 |
| 2026-11-16 | 162.78 |
| 2026-11-13 | 167.79 |
| 2026-11-12 | 166.52 |
| 2026-11-11 | 172.62 |
| 2026-11-10 | 173.98 |
| 2026-11-09 | 178.94 |
About this stock
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.